Status:
COMPLETED
Amlodipine/Atorvastatin Combination to Reduce the Health Risk of High Blood Pressure and High Cholesterol Levels
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Hypertension
Hyperlipidemia
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
The purpose of the study is to measure the effect of the amlodipine/atorvastatin combination pill in reducing both elevated blood pressure and cholesterol levels to levels suggested by guidelines
Eligibility Criteria
Inclusion
- Clinical diagnosis of both elevated blood pressure and low density lipoprotein cholesterol levels, requiring medication
Exclusion
- Patients with blood pressure adequately maintained at goal with or without medication
- Patients currently treated with both amlodipine and atorvastatin or not at blood pressure or lipid level while taking the highest dose of amlodipine or atorvastatin, respectively
Key Trial Info
Start Date :
May 1 2004
Trial Type :
INTERVENTIONAL
End Date :
July 1 2005
Estimated Enrollment :
1825 Patients enrolled
Trial Details
Trial ID
NCT00143234
Start Date
May 1 2004
End Date
July 1 2005
Last Update
January 27 2021
Active Locations (118)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Buenos Aires, Argentina, C1181ACH
2
Pfizer Investigational Site
Buenos Aires, Argentina, C1425ASS
3
Pfizer Investigational Site
Buenos Aires, Argentina, C1428DCO
4
Pfizer Investigational Site
Buenos Aires, Argentina, C1431FWO